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GUEST EDITORIAL
Vagus nerve stimulation for epilepsy: a review
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Guy’s, King’s and St. Thomas’s School of Medicine, King’s College Hospital, Denmark Hill, London
SE5 9RS, UK
Vagus nerve stimulation is an empirically based method for treatment of epilepsy by repeated stimulation of the left vagus nerve
through implanted electrodes. Despite studies in animals and man, which show changes in brain electrophysiology, metabolism
and neurochemistry, the mode of action remains unknown.
Clinical testing has presented methodological challenges, as it is difficult to assess under double blind conditions a treatment
which requires surgery and produces a sensation every time the stimulator comes on. This has nevertheless been successfully
addressed in parallel design, controlled trials comparing high and low stimulation schedules. These have been performed in
adults with medically intractable partial seizures, and demonstrated efficacy, safety and good tolerability. Efficacy, both in the
controlled trials and in numerous reports arising from the considerable post-marketing experience is modest. Some 30% of
patients achieve a 50% seizure reduction after 3 months of treatment, but this proportion progressively increases to about 50%
after 18 months.
Side-effects comprise: discomfort in the face or neck when the stimulator is activated, coughing, breathlessness on exertion
and hoarseness of voice. All are related to intensity of stimulation and rapidly habituate in most subjects. In those patients who
respond, a stimulus level can therefore generally be found which is acceptable to the subject.
No indication other than refractory partial seizures in adults has been the subject of controlled trials, but post-marketing ex-
perience and uncontrolled reports indicate comparable efficacy and safety in a wide range of epilepsies, partial and generalized,
idiopathic, cryptogenic, or symptomatic, in patients of all ages.
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INTRODUCTION
Vagal nerve stimulation (VNS) is a relatively novel
method of treatment for medically intractable epilepsy,
introduced in 1988, and used increasingly widely since
efficacy and safety were established by clinical trials
in the mid-1990s. It involves intermittent stimulation
of the left vagus in the neck by implanted electrodes
connected to a subcutaneous generator located below
the clavicle.
The use of VNS in epilepsy arises from the serendip-
itous experimental finding that extracranial vagal stim-
ulation desynchronizes the EEG in animals1, 2. As hy-
persynchrony is a feature of epileptic discharges and
arousal with EEG desynchronization blocks interictal
epileptiform activity in animal models and in man, it
was reasonable to test VNS for antiepileptic action
in experimental epilepsy. Several studies have shown
that VNS prevents, terminates or attenuates seizures
in various animal models (Table 1), including both
generalized seizures (PTZ, strychnine, maximal elec-
troshock) and partial (penicillin and alumina-gel foci,
amygdala kindling).
Zabara3 showed VNS suppressed within 0.5–5 sec-
onds seizures induced by continuous strychnine in-
fusion in the dog. Seizures returned 10 minutes
after termination of VNS. Thus the effects are rapid,
but outlast stimulation by some minutes, being half
maximal 5 minutes after termination4. Sustained stim-
ulation over a period of 60 minutes has a cumulative
effect4. Such observations, together with considera-
tions of battery life and the need to avoid damage to
the vagal nerve by prolonged stimulation, have led to
the general use in humans of a schedule of 30 second
stimulation at 5 minute intervals.
Despite extensive experimental studies and some
human data (Table 2), the mode of action of VNS is
unknown. With the stimulus parameters used in clin-
ical practice, vagal C-fibres are unlikely to be stimu-
lated, and destruction of C-fibres by capsaicin does not
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Table 1: Anticonvulsant effects of VNS in experimental epilepsies.
Year Investigators Model Animal Result
1938 Bailey and Bremer1 NA cat Induced frontal fast activity
1952 Zanchetti et al.2 Strychnine cat Blocked interictal spiking
1961 Magnes et al.51 NA cat Desynchronized EEG
1966 Chase et al.22 NA cat Synchronized or desynchronized EEG in thalamus and
cortex
1968 Stoica and Tudor52 Strychnine cat Increased or decreased cortical spiking
1971 O’Brien et al.53 NA monkey Elicited cortical evoked potentials
1977 Puizillout and Foutz54 NA cat Induced REM sleep
1985 Zabara3, 55 Strychnine dog Aborted seizures
1992
1990 Lockard et al.56 Alumina monkey Reduced seizure frequency
1991 Woodbury & Woodbury57 Maximal electroshock rat Reduced seizure severity
1993 McLachlan9 Penicillin/PTZ rat Reduced interictal spikes and seizure duration
1999 Fernandez-Guardiola et al.58 Amygdala kindling cat Delayed kindling, stage IV never reached
reduce the efficacy of VNS in animals5. The main cen-
tral afferent connection of the vagus is the nucleus of
the tractus solitarius (NTS), which projects to the lo-
cus coeruleus (LC) and adjacent parabrachial nucleus,
dorsal raphe, nucleus ambiguus, cerebellum, hypotha-
lamus, thalamus, insula, medullary reticular formation
and other brainstem structures, several of which are
known to modulate seizures in various models6–10.
Both chronic lesioning and acute inactivation of the
LC reduce the anticonvulsant effects of VNS11. How-
ever, the locus coeruleus has extensive diencephalic,
brainstem and cortical projections and the role of these
has not been explored by lesioning studies. Another
possibly relevant pathway is the projection of the NTS
through the parabrachial nuclei to the substantia in-
nominata and zona incerta. Stimulation of the areas
facilitates, and inhibition may suppress generalized
seizures12, 13. An alternative anatomical interpretation
is proposed by Rafael and Moromizato14, who suggest
that stimulation at mid-cervical level activates only
nocioceptive and proprioceptive afferents, which ter-
minate in subnuclei of the spinal trigeminal nucleus
(but not the NTS). These have projections to the cere-
bellum, medial accessory olivary nucleus, brainstem
reticular nuclei, LC, raphe and superior central nu-
clei. Changes in various neurotransmitters have been
demonstrated (Table 2), including an elevation of c.s.f.
GABA in man15 but whether these are secondary or
have a primary role in the mechanism of action of VNS
is unknown.
Photon emission tomography (PET) studies in man
have shown changes in blood flow in numerous corti-
cal and subcortical structures but with inconsistent re-
sults between subjects16–18. Similarly, fos-staining has
indicated activation by VNS at several apparently un-
related sites19.
In experimental animals VNS can produce desyn-
chronization or synchronization of the EEG, depend-
ing on the stimulus parameters used20–22; but signif-
icant EEG changes in man have not been demon-
strated23–25.
PRACTICAL AND SURGICAL DETAILS
Human experience is confined to a single device, the
Neurocybernetic Prosthesis (NCPr) developed and
marketed by Cyberonics (Webster, TX, USA). The
system comprises: a pulse generator, a lead incorpo-
rating a bipolar electrode, tether and connectors, a tun-
nelling tool, a programming wand with control soft-
ware and a magnet.
The electrode array comprises 2 silicone helices
each with three turns, with a platinum ribbon electrode
within the middle turn. Threads are attached to posi-
tion the coils around the nerve. A third helical coil is
located further caudally to tether the lead to the nerve.
The generator is a disc of 55 mm diameter and
13.2 mm thick, weighing 55 mg. Both before and after
implantation it can be interrogated and programmed
by radio-frequency signals from the wand which is
connected to the serial port of a laptop computer. Out-
put current, pulse width and frequency, the duration of
each stimulus train and intervals between trains can
be selected. The software also tests the integrity of
the generator and lead during implantation. The set-
tings can subsequently be recovered by interrogating
the generator.
A hand-held magnet can be used to turn on stimu-
lation when briefly placed over the generator and set-
tings for magnet-activated stimulation can also be pro-
grammed. If the magnet is left in place over the gen-
erator, the device is inactivated; this facility can be
used to suspend stimulation at times when side-effects
would be inconvenient (see below).
Implantation is performed under general anaesthe-
sia and the surgical procedure takes approximately
1 hour in experienced hands. The electrodes are placed
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Table 2: Evidence on mode of action of VNS.
Functional anatomy:-
Multiple projection pathways identified, through nucleus of the tractus solitarius to:
locus coeruleus, parabrachial nucleus, dorsal raphe, nucleus ambiguus, cerebellum, hypothalamus, thalamus, insula,
medullary reticular formation, substantia innominata, zona incerta.
Lesioning/inactivation of locus coeruleus reduces the anticonvulsant effect5.
PET:-
Blood flow increased in rostral medulla, right post-central gyrus, hypothalami, thalami, insulae, cerebellum.
Blood flow decreased in hippocampi, amygdalae, posterior cinguli17.
Electrophysiology:-
EEG desynchronized or synchronized in cat22, 51.
Little effect on in man23, 25.
Evoked potential latencies increased in man59, or no effect24.
Neurochemistry:-
Serotoninergic: csf 5-hydroxyindole acetic acid increase60.
Serotoninergic: Activation of loculus coeruleus11.
Dopaminergic: csf homovanillic acid elevated15.
GABAergic: csf GABA elevated15; Vth nerve nucleus response to Gasserian stimulation reduced61;
vagal nerve lesioning by ibotenic acid reduces threshold to
picrotoxin & bicuculline but not strychnine (Godlevsky et al. 1994).
VNS induces fos production in superior colliculus, amygdala, cortex, post-lateral thalamus and hypothalamus19.
through an incision over the anterior border of the left
sternomastoid midway between the mastoid process
and the clavicle. The nerve is identified in the carotid
sheath, is mobilized and lifted with vessel loops. The
coils are applied to the vagus and gentle traction ap-
plied to the threads to wrap them around the nerve.
A horizontal incision is then made, centred on a point
below the mid-point of the left clavicle and a subcuta-
neous pouch is prepared to receive the generator. The
tunnelling tool is used to pass the connectors of the
lead from the cervical to the thoracic incision. The lead
is plugged into the generator. This is then interrogated
by means of the wand and a lead integrity test is run.
Procedures for starting stimulation vary. It is rec-
ommended that stimulation be withheld for 2 weeks
as current may track along pathways formed by post-
operative oedema. Subsequent ramping up of current
is determined by clinical response, tolerability and
timing outpatient visits to suit the convenience of the
patient. An increase in current as small as 0.25 mA
is generally experienced as disagreeable. The patient
complains of discomfort or pain in the neck, jaw,
face or teeth, and may suffer a paroxysm of cough-
ing. The voice may be strikingly altered. These symp-
toms rapidly subside, so that after two or three cy-
cles of stimulation the patient reports them as being
unpleasant but tolerable and within a few hours sig-
nificant discomfort has generally disappeared. Current
escalation continues until a good therapeutic response
is obtained, or adverse symptoms become persistent
(see below) or until the maximum available setting of
3.5 mA is reached.
EVIDENCE OF EFFICACY
The first patient treated by VNS, showed a marked
reduction in seizure frequency26. Single-blind (desig-
nated E01 and E02) studies followed in 14 patients,
also giving results sufficiently encouraging to justify
more formal trials (Table 4).
There are obvious practical difficulties in assessing
a treatment which involves surgery and produces ob-
vious side-effects. Randomized, controlled trials have
been conducted, using a parallel, add-on design un-
der so far as possible double-blind conditions. Both
were multicentre studies using similar designs, desig-
nated E0327 and E0528, and involving 114 and 199 pa-
tients, respectively. The patients (Table 3) had medi-
cally intractable partial seizures, with or without sec-
ondary generalization. After a baseline period of 3 to
4 months, they were randomized to one of two treat-
ments. The standard protocol (designated ‘high stim-
ulation’) was that thought from previous studies to
be most effective. It comprised 30 second periods of
stimulation at 5 minute intervals, at the maximum tol-
erated current. The alternate treatment (‘low stimula-
tion’) was regarded as a less effective active control,
but it is uncertain whether it was in fact of minimal or
zero efficacy. It used a 30 second stimulation period
at 60–180 minute intervals, and a lower pulse rate and
duration, at a current level just above the threshold for
sensation; magnet-triggered stimulation was disabled.
At each site, physical examination, and documenta-
tion of seizure frequency and adverse events were per-
formed by blinded investigators, and, programming of
the generator by an independent investigator.
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Table 3: Studies E03 and E05—patient characteristics.
E03 E05
Inclusion criteria
age over 12 yrs 12–65
seizures 6 or more per month 6 or more complex partial
maximum interval 14 days refractory maximum interval 21 days refractory
predominantly partial
AEDs 1–3 1–3 with stable levels
contraception acceptable method
documentation patient or carer can accurately record seizures
Exclusion criteria
progressive neurological disorder +
unstable medical condition +
pregnancy +
investigational AED +
active peptic ulcer +
current +
cardiac/pulmonary disease
prior vagotomy or VNS +
AEDs prn +
>2 episodes of status in past year +




age (mean yrs) 33 33
male % 62 47
mean seizures/day 1.62 1.26
duration of epilepsy 22 yrs 23 yrs
number of AEDs 2.08 2.1
% with secondary GT-C seizures 35 51
Table 4: Efficacy of VNS in trials E01, 2, 3, 4, and 5.
% Change in seizure frequency (n) % with >50% seizure reduction
Study High Low P High Low P
E01/2 −28.2 (14) NA <0.05 14.3 NA NS
E03 −24.5 (54) −6.1 (60) <0.01 31.0 13.0 <0.02
E04 −21.5 (116) NA <0.001 29.3 NA NS
E05 −27.9 (94) −15.2 (102) 0.039 23.4 15.7 NS
One hundred and twenty-five patients were enrolled
for the E03 study, 114 of whom underwent random-
ization. For E05, 254 were recruited but 55 were with-
drawn during the baseline period, and one was with-
drawn due to infection of the implant site; thus 199
were randomized. In both studies, the clinical char-
acteristics of the two treatment groups were closely
similar. The primary efficacy measure was percent-
age change in seizure frequency with respect to base-
line during the 12 weeks following ramp up. A sec-
ondary outcome measure was the proportion of sub-
jects experiencing a 50% seizure reduction. In E03,
mean seizure frequency fell by 24.5% on high and
6.1% on low stimulation; in E05 the reductions were
28% and 15%, respectively; a significant difference in
favour of high stimulation in both cases. Fifty percent
seizure reduction was achieved by 31% of the high and
13% of the low stimulation groups in E03 (P < 0.02).
In E05, there was a 50% reduction in 23.4% on high
and 15.7% on low stimulation, a difference which was
not significant; however, 10.6 and 2.0, respectively,
achieved a 75% reduction (P < 0.015). Only three pa-
tients (two in E03 and one in E05) became seizure-free
after the 3-month acute period of the assessment.
Table 4 summarizes the efficacy data from the ran-
domized trials E03 and E05, the early studies, E01-
2, and a subsequent, larger open study E04. That high
level VNS was associated with seizure reduction is not
in doubt, but the strength of the effect is impossible to
assess. In all studies there may have been a ‘placebo
effect’, including possible regression to mean seizure
frequency in patients who were recruited during a
temporary exacerbation of their epilepsy. As it is not
known whether low stimulation had any antiepilep-
tic action, it is impossible to assess the placebo ef-
fect. Nevertheless it may be noted that, irrespective
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of any possible placebo component, response rates for
high stimulation, by all measures used (except pos-
sibly subjects becoming seizure-free) were similar to
those in trials, in similar patient populations, of re-
cently registered new antiepileptic drugs29, 30.
SAFETY AND TOLERABILITY
This method of treatment raises issues about safety in
several areas. Electrical damage to tissue should not
occur at the maximum settings of current and duty cy-
cle available (maxima 3.5 mA, 14 V and 0.36, respec-
tively) and indeed there is no evidence of nerve in-
jury31, 32. Magnetic resonance image (MRI) scanning
could in theory cause heating of the leads, but is ap-
proved in the USA, provided only a head coil is used,
and by KEMA in Europe. The device is not affected
by microwave transmissions, cellular phones or air-
port security systems, but the author knows one patient
whose stimulator was twice activated during take-off
or landing, presumably by fields from actuators used
to operate the spoilers or undercarriage.
Some surgical complications may be expected, par-
ticularly from insertion of a prosthetic device. In the
E03 study, the battery of one generator failed. Another
generator locked in continuous high output mode,
causing left vocal cord paralysis. In one case the lead
became disconnected from the generator and had to
be re-connected. One patient suffered a reversible left
lower facial paresis and one had an infection at the im-
plant site which was controlled by antibiotics. In the
E05 study, operative and technical complications were
all reversible and comprised: left vocal cord paresis
(two patients), left lower facial paresis2 fluid accumu-
lation around the generator1 and infection around the
device requiring removal3. No damage to the common
carotid artery has been reported during post-marketing
surveillance of some 4500 patients (Cyberonics inter-
nal data).
Possible peripheral vagal effects are a further con-
cern, but measures are adopted to minimize these.
Only the left vagus is used for VNS; this is mainly
afferent and in particular contains less cardiac effer-
ent fibres than the right. In both the randomized con-
trolled trials particular attention was directed to pos-
sible peripheral vagal effects. In the E03 study, vital
signs, routine EKG, Holter monitoring (in 28 subjects)
and assays of gastric acid (14 patients) were inves-
tigated. In E05, vital signs were checked and Holter
monitoring (mean heart rate, lowest and peak heart
rate, heart rate variability and episodes of bradycar-
dia) were checked in all subjects at baseline and after
ramp up, as were fasting serum gastrin and pulmonary
function. No evidence of adverse effects of peripheral
vagal stimulation was found. There are reports of re-
versible asystole during intraoperative testing of the
stimulator in five patients33, 34. This may have been
due to anaesthesia, as various anaesthetic agents dif-
ferentially suppress both sympathetic and parasym-
pathetic tone, with the possibility of increasing car-
diac effects of vagal stimulation35, 36. Until further ev-
idence is obtained it would appear advisable to initiate
VNS during implantation only with great care and un-
der cardiac monitoring and to inactivate the generator
during any subsequent general anaesthetic.
No patient died during the E03 and E05 trials, but
cases of sudden, unexpected death (SUDEP) have
been reported. A study by Annegers et al.37 of 791 pa-
tients followed over 1335 patient years, found an in-
cidence of definite or probable SUDEP in patients un-
dergoing VNS of 4.5 per 1000 patient years, which is
no greater than expected in such a population.
One patient in E03 suffered a non-fatal myocardial
infarct and was withdrawn. In E05, two patients were
withdrawn after randomization, one because of post-
ictal Cheyne–Stokes respiration which continued after
deactivation of the device, the other because of multi-
ple symptoms present before, during and after termi-
nation of VNS.
Levels of co-medication, serum chemistry, haema-
tology and urinalysis were checked in both trials and,
not unexpectedly, no adverse effects were detected.
Subjective stimulus-related adverse experiences are
reported by all patients able to communicate, and
include pain or discomfort, alteration of the voice,
breathlessness and coughing. These are generally mild
and show rapid habituation until the maximum tol-
erated current setting is reached. Voice changes are
usually mild, but during stimulation the speaker may
sound anxious or appear to have a sore throat. This
may not be obvious to any but the most attentive lis-
tener, but can be embarrassing to the patient whose
work brings them into contact with the public. Cough-
ing and dyspnoea may be troublesome to those who
engage in vigorous exercise, but can be avoided by
strapping a magnet over the generator to inactivate the
device during physical exertion. Some patients with
learning disability suffer dysphagia and aspiration has
been reported38. This too may be avoidable by appli-
cation of the magnet at mealtimes.
In both trials, the adverse experience most often
reported on high stimulation was hoarseness/voice
change (37.2% in E03; 63% in E05). The discrep-
ancy between the trials may reflect different meth-
ods of questioning; in E05 adverse experience reports
were actively solicited. Nevertheless, all patients are
aware of stimulation and, as few become seizure-free,
a strategy of treating to the limits of tolerance will
necessarily result in most patients eventually experi-
encing significant side-effects. Any reported incidence
of stimulation-related side-effects less than 100% is
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therefore virtually meaningless without further qual-
ification. Discomfort and voice changes are usual,
but rapidly habituate until the limits of tolerance are
reached; a setting should then be selected which is ac-
ceptable to the patient.
The completion rates for the studies, 98% in E03
and 99% in E05, are strikingly higher than those for
antiepileptic drug trials in similar populations; the lack
of side-effect-related withdrawals suggests a high tol-
erability of this treatment.
LONG TERM OUTCOME
Patients randomized to low stimulation in the E03
study were subsequently switched to the high stimu-
lus schedule. During 18 month follow-up of the first
67 patients to complete the blinded study, both groups
continued to improve, but those transferred from low
to high stimulation lagged behind those on the high
regime. Thus after a total of 15 months on high stim-
ulation all patients showed a similar mean seizure
reduction: 43.1% in the original ‘high’ group and
marginally less, 38.1%, in the former ‘low’ group (i.e.
after 18 months in all)39. However, the degree of im-
provement is hard to assess as 10% of patients with-
drew because of lack of efficacy, and there were miss-
ing data in others.
Salinsky et al.40 analysed the results of 12 months
‘high’ stimulation in the E03 study on a last-visit-
carried-forward basis and found 32.1% and 31.6%
seizure reductions in the former high and low groups,
respectively.
Despite this continuing improvement, response
within the first 3 months on high stimulation was pre-
dictive of long term outcome. Twenty-eight percent
of patients achieved a 50% seizure reduction after
3 months, and only 3% more did so after 1 year.
In a follow-up of the E05 study, 102 subjects were
transferred from ‘low’ to ‘high’ stimulation, and ‘94’
continued on the high schedule. After a further 3
months, the reduction in seizure frequency with re-
spect to baseline increased from 15% to 34% in the
former ‘low’ group, and from 28% to 46% in the
‘high’ group, relative improvements in seizure control
of 125% and 45%41.
The longest follow-up experience (mean 20 months,
range 3 to 64 months) is reported by Ben-Menachem et
al.42 in 64 patients not apparently included in the E03
and E05 studies. If a new drug was introduced to im-
prove efficacy, evaluation of VNS outcome was termi-
nated. Forty-four percent experienced a 50% seizure
reduction (5/8, 63%, both in Lennox Gastaut syn-
drome and 5/8 in ‘primary generalized seizures’).
These studies should be interpreted with caution
as they were unblinded, adjustment of co-medication
was permitted and some patients were lost to follow-
up or withdrew because of lack of efficacy. The most
comprehensive available data set analysed on a basis
of last-visit-carried-forward comprised 244 patients
from the E01, E02, E03 trials and a further open study,
E04. There was a mean change in seizure frequency
of −38.7% after 18 months, with 37.7% of patients
achieving a 50% seizure reduction (Cyberonics, in-
ternal report). Despite their limitations, the follow-up
studies support the contention that high stimulation is
more efficacious than low, and suggest a continuing
cumulative effect of VNS beyond the first 3 months of
treatment.
PAEDIATRIC RESULTS
No formal controlled paediatric trials have been re-
ported, but there is considerable reported experience
of VNS in children. Murphy et al.43 reported a seizure
reduction of more than 90% in five out of 12 chil-
dren with intractable epilepsy. Schallert et al.44 and
Lundgren et al.45, respectively, found that 12 out of 20
and six of 16 children achieved a 50% seizure reduc-
tion. Some limited assessments of quality of life in-
dicated worthwhile improvement in 17. Parker et al.46
investigated 16 children with particularly severe symp-
tomatic or cryptogenic generalized epilepsies, who
had been found unsuitable for surgery. Initial response
was poor but after 2 years of follow-up, there was
a mean seizure reduction of 46%, six patients had
achieved a 50% seizure reduction, one was seizure-
free, and five had objective evidence of improved qual-
ity of life.
OUTSTANDING ISSUES
Mode of action. An understanding of the mode of
action has not been found essential to either the
acceptance or effective use of novel antiepileptic
drugs (AEDs). Nevertheless, establishing the mech-
anisms underlying the anticonvulsant action of VNS
would enhance its credibility and might facilitate the
identification of optimal treatment protocols and of
suitable or unsuitable co-medication, and selection of
the most appropriate patients.
Stimulation parameters. The standard protocol of
30 second stimulation at 5 minute intervals was se-
lected on the basis of the duration of effect in animal
models, but has not been shown to be optimal in man.
At least three other schedules are in use: ‘rapid cy-
cling’: 7 second stimulation at 0.3 minute intervals,
1 minute continuous stimulation at 5 minute intervals,
and 30 seconds at 1.8 minute intervals. No formal
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studies have compared these protocols nor determined
whether there are different indications for their use.
Interactions with drugs. Studies of mode of action of-
fer some evidence that the effects of VNS are mediated
by specific neurotransmitters. If this is so, there may
also be synergy or antagonism between VNS and par-
ticular drugs, which need to be considered when VNS
is used in patients taking AEDs, or other agents.
Identification of candidates. Although the controlled
trials included only patients with partial seizures, it
appears from uncontrolled reports and post-marketing
experience that VNS exhibits the same, modest effi-
cacy in a wide range of epilepsies and seizure types,
both partial and generalized47, 48. In pharmacotherapy
of epilepsy, a wide spectrum of action is generally
regarded as an advantage, but until a wide spectrum
of action is reliably established, or narrower indica-
tions are more clearly defined, there will be justified
concern that vagal nerve stimulation is not being used
optimally.
At present it appears that VNS should be considered
in any patient with undoubted epilepsy, demonstrably
resistant to appropriate medication administered to tol-
erance, who is not a candidate for potentially curative
resective surgery. The definition of medical intractabil-
ity may be disputed, and similar considerations will
apply as in conventional surgery. It is a matter of con-
cern that VNS may be viewed, both by physicians and
patients, as a safe, inexpensive alternative to resective
surgery. As the latter offers to some categories of pa-
tients a 70–85% chance of complete seizure control,
it is important that VNS should only be undertaken
after full consideration of other surgical options, and
in the context of a comprehensive epilepsy program.
Vagal nerve stimulation offers palliative treatment ap-
proximately equivalent in efficacy to callosotomy, and
a randomized trial of VNS and callosotomy would be
valuable.
Benefits other than seizure control. There is some
anecdotal evidence that VNS improves cognition, par-
ticularly in patients with learning disability and may
improve mood and quality of life. As noted above,
quality of life measures were included in some un-
controlled paediatric trials and benefits were claimed.
Clark et al.49 report enhancement of retention mem-
ory in a robust controlled study in man. Unfortunately,
this effect was seen only at levels of current too low
to influence seizure frequency in most subjects. Fur-
ther randomized studies of cognitive, affective and be-
havioural changes during VNS at therapeutic levels are
urgently required.
Vagal nerve stimlation as an alternative to pharma-
cotherapy. Although side-effects of VNS are in-
escapable, they are well tolerated and cause less
distress and impairment of quality of life than
do the cognitive side-effects of most AEDs. If
further experience of VNS in intractable epilep-
sies is favourable, the question must arise as to
whether this treatment may not also be suitable
for some patients whose seizures are controllable
with AEDs, but only at a cost of unacceptable
side-effects. Comparative cost/benefit studies against
AEDs in less refractory populations must be the next
step.
Cost-benefit. The efficacy of vagus nerve stimulation
appears to be comparable to, or greater than, that of
any one of the newer antiepileptic drugs; however, trial
use of a drug can rapidly be abandoned if unsuccess-
ful, whereas undertaking treatment by VNS involves a
minimum commitment to the cost of the device and its
implantation. Nevertheless, across a sample of 15 pa-
tients including responders and non-responders, the
cost of VNS was recovered by savings in direct medi-
cal costs within 2 years50.
Regulatory status. Vagal nerve stimulation is recog-
nized as effective by the US Food and Drug Admin-
istration, Medicare and the central advisory board of
Blue Cross-Blue Shield. The device has E.U. CE ap-
proval. A report of the American Academy of Neurol-
ogy’s Therapeutics and Technology Assessment Sub-
committee, Fisher and Handforth30 concludes the ev-
idence of efficacy to be of Class I, except for use in
idiopathic generalized epilepsies and children, where
is it of Class III.
CONCLUSION
Vagus nerve stimulation offers a non-pharmacological
palliative treatment of epilepsy, of established effi-
cacy and safety in adults with medically refractory
partial seizures which are not amenable to resec-
tive surgery. In this population the efficacy is mod-
est but worthwhile and the tolerability excellent. Ran-
domized controlled trials are not available in other
seizure types nor in children, but VNS appears to be
of similar efficacy in all forms of intractable epilepsy.
Its utility in milder seizure disorders is unknown.
The eventual overall role of this therapy in epilepsy
has yet to be established, but is likely to be signifi-
cant.
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